Cubosomes in cancer drug delivery: A review

The lyotropic nonlamellar liquid crystalline nanoparticles (LCNs), especially cubosomes are gaining utility and acceptance as a drug delivery system, in diseases like cancer. These cubosomes are highly versatile carriers with promising theranostic efficiency and can be administered via oral, topical, or intravenous modalities. Over the recent years, significant research has facilitated the improvement in the efficacy, preparation, characterization, target selectivity, and controlling drug release profiles of the loaded anticancer bioactive. Nonetheless, its clinical translation has been slow and additionally requires concrete evidence. This review underscores the recent advances and impediments in the development and application of cubosomes against various cancers and discussing the hurdles faced in segueing it into a potential nanotechnological intervention. This review encompasses the various anti-cancer drugs that have been studied for the loading onto the Cubosomal nanoparticles, which are being greatly studied in the recent years. It also sheds light on the effectiveness of these lipid-based nanoparticles, which are thought to be the future of drug delivery. [Display omitted] •The utility of cubosomal nanoparticles in drug delivery systems•Cubosomes in delivering established anticancer drugs in various cancers.•Preparation, Characterization, and Drug Release Studies for drug-loaded cubosomes•Advances and Impediments in their Development and Application in Cancer Treatment